EcoDrugPlus

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSOTSG00005024837
Gene Symbol: MAPK11
1 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSOTSG00005008618
Gene Symbol: MAPK11
1 Cross references
196 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSOTSG00005030283
Gene Symbol: MAPK14
1 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSOTSG00005033067
Gene Symbol: MAPK14
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSOTSG00005005030
Gene Symbol: LOC112221833
3 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase 14b

Ensembl ID : ENSOTSG00005029649
Gene Symbol: MAPK14B
1 Cross references
217 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSOTSG00005006178
Gene Symbol: MAPK3
1 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSOTSG00005034078
Gene Symbol: MAPK3
1 Cross references
192 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSOTSG00005035094
Gene Symbol: LOC112223506
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSOTSG00005047987
Gene Symbol: LOC112252764
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSOTSG00005010785
Gene Symbol: MAPK8A
1 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSOTSG00005012892
Gene Symbol: MAPK8B
1 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).